Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance

Cancer Biology and Therapy

Volumn 10, Issue 11, 2010, Pages 1126-1136

  Barth, Brian M ^a,b   Gustafson, Sally J ^a   Young, Megan M ^b   Fox, Todd E ^b   Shanmugavelandy, Sriram S ^b   Kaiser, James M ^b   Cabot, Myles C ^c   Kester, Mark ^b   Kuhn, Thomas B ^a  

^a UNIVERSITY OF ALASKA FAIRBANKS   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Antioxidant; Ceramide; Chemoresistance; Glioblastoma; Glucosylceramide; Glucosylceramide synthase; NADPH oxidase; Nanoliposome; Neuroblastoma

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; FENRETINIDE; GEMCITABINE; GLUCOSYLCERAMIDE; LIPOSOME; METHOTREXATE; PACLITAXEL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TAMOXIFEN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; UPREGULATION;

CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; HUMANS; NADPH OXIDASE; NEUROBLASTOMA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649815908     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.11.13438     Document Type: Article

References (38)

1. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radic Biol Med 2001; 31:717-28.
2. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-16.
3. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, et al. Ceramides and other bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006; 1758:1864-84.
4. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 2007; 87:245-313. (Pubitemid 46209993)
5. Cacicedo JM, Benjachareowong S, Chou E, Ruderman NB, Ido Y. Palmitate-induced apoptosis in cultured bovine retinal pericytes: Roles of NAD(P)H oxidase, oxidant stress and ceramide. Diabetes 2005; 54:1838-45. (Pubitemid 40770775)
6. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274:1855-9.
7. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 2001; 93:347-57.
8. Lambeth JD, Kawahara T, Diebold B. Regulation of nox and duox enzymatic activity and expression. Free Radic Biol Med 2007; 43:319-31.
9. Lambeth JD. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. Curr Opin Hematol 2002; 9:11-7.
10. Graham KA, Kulawiec M, Owens KM, Li X, Desouki MM, Chandra D, et al. NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol Ther 2010; 10.
11. Wang R, Dashwood WM, Nian H, Lohr CV, Fischer KA, Tsuchiya N, et al. NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Int J Cancer 2010; [Epub ahead of print].
12. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009; 23:1432-40.
13. Richards SM, Clark EA. BCR-induced superoxide negatively regulates B-cell proliferation and T-cell-independent type 2 ab responses. Eur J Immunol 2009; 39:3395-403.
14. Belda-Iniesta C, de Castro Carpeno J, Casado Saenz E, Cejas Guerrero P, Perona R, Gonzalez Baron M. Molecular biology of malignant gliomas. Clin Transl Oncol 2006; 8:635-41.
15. Smith PS, Zhao W, Spitz DR, Robbins ME. Inhibiting catalase activity sensitizes 36B10 rat glioma cells to oxidative stress. Free Radic Biol Med 2007; 42:787-97. (Pubitemid 46298664)
16. Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta 2006; 1758:2096-103.
17. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001; 15:719-30.
18. Liel Y, Rudich A, Nagauker-Shriker O, Yermiyahu T, Levy R. Monocyte dysfunction in patients with gaucher disease: Evidence for interference of glucocerebroside with superoxide generation. Blood 1994; 83:2646-53. (Pubitemid 24135858)
19. Barth BM, Stewart-Smeets S, Kuhn TB. Proinflammatory cytokines provoke oxidative damage to actin in neuronal cells mediated by Rac1 and NADPH oxidase. Mol Cell Neurosci 2009; 41:274-85.
20. Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci 2007; 96:2181-96.
21. Wang J, Yi J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol Ther 2008; 7:1875-84.
22. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001; 61:5102-5.
23. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, et al. N-(4-hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 2008; 7:2967-76.
24. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005; 11:3465-74.
25. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008; 14:3571-81.
26. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 2008; 36:1709-15.
27. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008; 68:7638-49.
28. Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 2009; 8:1831-7.
29. Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, et al. Growth of human pancreatic cancer is inhibited by downregulation of gastrin gene expression. Pancreas 2009; 38:151-61.
30. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 2008; 9:112-24.
31. phox. Mol Biol Cell 2007; 18:441-54.
32. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000; 10:73-80.
33. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139-50.
34. Moskwa P, Palicz A, Paclet MH, Dagher MC, Erdos M, Marodi L, et al. Glucocerebroside inhibits NADPH oxidase activation in cell-free system. Biochim Biophys Acta 2004; 1688:197-203.
35. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3:16-20.
36. Castel V, Grau E, Noguera R, Martinez F. Molecular biology of neuroblastoma. Clin Transl Oncol 2007; 9:478-83.
37. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8:57-69. (Pubitemid 46011999)
38. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: A matter of fat. J Neurochem 2007; 101:577-99. (Pubitemid 46633316)